Furthermore, for lipid-lowering therapy, a particular siRNAs is revolutionizing the therapeutical approach to hypercholesterolemia: inclisiran, which achieves significant reduction in PCSK9 expression and subsequently in LDL levels with just two doses per year [103]. Here, PCSK9 is linked to familial hypercholesterolemia.